Blair JC, et al. - In children and young people, researchers compared the effectiveness, safety, and cost utility of continuous subcutaneous insulin infusion (CSII) vs multiple daily injection (MDI) regimens during the first year after type 1 diabetes diagnosis. In this pragmatic, multicenter, open label, parallel group, randomized controlled trial, 294 patients were randomized and 293 included in the intention to treat analyses. CSII was not found to be cost-effective. During the first year after type 1 diabetes diagnosis, no clinical benefit was seen with CSII over MDI in children and youth in the UK; in achieving HbA1c thresholds, treatment with either regimen was suboptimal.